Interestingly, the ALT data on day 2 showed that the liver function of the AAV-treated group was better than that of the LY2157299-treated group, the latter being not significantly different from the NC group (Figure 5D), suggesting that weakening of liver fibrosis, not inhibition of TGFβ1, improves liver function. Here, TGFB1 is linked to Hepatic fibrosis.